within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP11_Grazoprevir;

model Grazoprevir
  extends Pharmacolibrary.Drugs.ATC.J.J05AP11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AP11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Grazoprevir is an oral inhibitor of the hepatitis C virus (HCV) NS3/4A protease, approved for use in combination with elbasvir for the treatment of chronic HCV genotype 1 and 4 infections in adults. It is used as part of direct-acting antiviral regimens and is currently approved and used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects, oral administration of single 100 mg dose.</p><h4>References</h4><ol><li><p>Sulejmani, N, et al., &amp; Gordon, SC (2016). Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. <i>Expert opinion on drug metabolism &amp; toxicology</i> 12(3) 353–361. DOI:<a href=&quot;https://doi.org/10.1517/17425255.2016.1148685&quot;>10.1517/17425255.2016.1148685</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26849059/&quot;>https://pubmed.ncbi.nlm.nih.gov/26849059</a></p></li><li><p>Karaoui, LR, et al., &amp; Chahine, EB (2017). Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 74(19) 1533–1540. DOI:<a href=&quot;https://doi.org/10.2146/ajhp160558&quot;>10.2146/ajhp160558</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28947524/&quot;>https://pubmed.ncbi.nlm.nih.gov/28947524</a></p></li><li><p>Li, H, et al., &amp; Mu, S (2020). A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants. <i>Clinical pharmacology : advances and applications</i> 12 1–11. DOI:<a href=&quot;https://doi.org/10.2147/CPAA.S224662&quot;>10.2147/CPAA.S224662</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32104104/&quot;>https://pubmed.ncbi.nlm.nih.gov/32104104</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Grazoprevir;
